ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Immune Checkpoint Agents Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-31V8457
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Immune Checkpoint Agents Market Insights Forecast to 2028
BUY CHAPTERS

Global Immune Checkpoint Agents Market Research Report 2025

Code: QYRE-Auto-31V8457
Report
January 2025
Pages:71
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bristol–Myers Squibb
Merck
Astrazeneca plc
Roche

Immune Checkpoint Agents Market

The global market for Immune Checkpoint Agents was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Immune Checkpoint Agents are a class of drugs used in cancer treatment that help the body fight cancer cells by modulating the function of the immune system. Immune checkpoints are biological mechanisms that help maintain the balance of the immune system and prevent it from attacking normal cells. However, some cancer cells can use this mechanism to evade immune system attack.
North American market for Immune Checkpoint Agents is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Immune Checkpoint Agents is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Immune Checkpoint Agents include Bristol Myers Squibb, Merck, AstraZeneca, Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Immune Checkpoint Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Checkpoint Agents.
The Immune Checkpoint Agents market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immune Checkpoint Agents market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune Checkpoint Agents manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Immune Checkpoint Agents Market Report

Report Metric Details
Report Name Immune Checkpoint Agents Market
Segment by Type
  • Anti-PD-L1 Drug
  • Anti-PD-1 Drug
  • CTLA4
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bristol Myers Squibb, Merck, AstraZeneca, Roche
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Immune Checkpoint Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Immune Checkpoint Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Immune Checkpoint Agents Market report?

Ans: The main players in the Immune Checkpoint Agents Market are Bristol Myers Squibb, Merck, AstraZeneca, Roche

What are the Application segmentation covered in the Immune Checkpoint Agents Market report?

Ans: The Applications covered in the Immune Checkpoint Agents Market report are Lung Cancer, Colorectal Cancer, BreastCancer, Prostate Cancer, Melanoma, Blood Cancers

What are the Type segmentation covered in the Immune Checkpoint Agents Market report?

Ans: The Types covered in the Immune Checkpoint Agents Market report are Anti-PD-L1 Drug, Anti-PD-1 Drug, CTLA4

Recommended Reports

Immunotherapy Markets

Oncology Therapeutics

Cancer Treatment Devices

1 Immune Checkpoint Agents Market Overview
1.1 Product Definition
1.2 Immune Checkpoint Agents by Type
1.2.1 Global Immune Checkpoint Agents Market Value Comparison by Type (2024 VS 2031)
1.2.2 Anti-PD-L1 Drug
1.2.3 Anti-PD-1 Drug
1.2.4 CTLA4
1.3 Immune Checkpoint Agents by Application
1.3.1 Global Immune Checkpoint Agents Market Value by Application (2024 VS 2031)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 BreastCancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancers
1.4 Global Immune Checkpoint Agents Market Size Estimates and Forecasts
1.4.1 Global Immune Checkpoint Agents Revenue 2020-2031
1.4.2 Global Immune Checkpoint Agents Sales 2020-2031
1.4.3 Global Immune Checkpoint Agents Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Immune Checkpoint Agents Market Competition by Manufacturers
2.1 Global Immune Checkpoint Agents Sales Market Share by Manufacturers (2020-2025)
2.2 Global Immune Checkpoint Agents Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Immune Checkpoint Agents Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Immune Checkpoint Agents, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Immune Checkpoint Agents, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Immune Checkpoint Agents, Product Type & Application
2.7 Global Key Manufacturers of Immune Checkpoint Agents, Date of Enter into This Industry
2.8 Global Immune Checkpoint Agents Market Competitive Situation and Trends
2.8.1 Global Immune Checkpoint Agents Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Immune Checkpoint Agents Players Market Share by Revenue
2.8.3 Global Immune Checkpoint Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Immune Checkpoint Agents Market Scenario by Region
3.1 Global Immune Checkpoint Agents Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Immune Checkpoint Agents Sales by Region: 2020-2031
3.2.1 Global Immune Checkpoint Agents Sales by Region: 2020-2025
3.2.2 Global Immune Checkpoint Agents Sales by Region: 2026-2031
3.3 Global Immune Checkpoint Agents Revenue by Region: 2020-2031
3.3.1 Global Immune Checkpoint Agents Revenue by Region: 2020-2025
3.3.2 Global Immune Checkpoint Agents Revenue by Region: 2026-2031
3.4 North America Immune Checkpoint Agents Market Facts & Figures by Country
3.4.1 North America Immune Checkpoint Agents Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Immune Checkpoint Agents Sales by Country (2020-2031)
3.4.3 North America Immune Checkpoint Agents Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Immune Checkpoint Agents Market Facts & Figures by Country
3.5.1 Europe Immune Checkpoint Agents Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Immune Checkpoint Agents Sales by Country (2020-2031)
3.5.3 Europe Immune Checkpoint Agents Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Immune Checkpoint Agents Market Facts & Figures by Region
3.6.1 Asia Pacific Immune Checkpoint Agents Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Immune Checkpoint Agents Sales by Region (2020-2031)
3.6.3 Asia Pacific Immune Checkpoint Agents Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Immune Checkpoint Agents Market Facts & Figures by Country
3.7.1 Latin America Immune Checkpoint Agents Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Immune Checkpoint Agents Sales by Country (2020-2031)
3.7.3 Latin America Immune Checkpoint Agents Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Immune Checkpoint Agents Market Facts & Figures by Country
3.8.1 Middle East and Africa Immune Checkpoint Agents Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Immune Checkpoint Agents Sales by Country (2020-2031)
3.8.3 Middle East and Africa Immune Checkpoint Agents Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Immune Checkpoint Agents Sales by Type (2020-2031)
4.1.1 Global Immune Checkpoint Agents Sales by Type (2020-2025)
4.1.2 Global Immune Checkpoint Agents Sales by Type (2026-2031)
4.1.3 Global Immune Checkpoint Agents Sales Market Share by Type (2020-2031)
4.2 Global Immune Checkpoint Agents Revenue by Type (2020-2031)
4.2.1 Global Immune Checkpoint Agents Revenue by Type (2020-2025)
4.2.2 Global Immune Checkpoint Agents Revenue by Type (2026-2031)
4.2.3 Global Immune Checkpoint Agents Revenue Market Share by Type (2020-2031)
4.3 Global Immune Checkpoint Agents Price by Type (2020-2031)
5 Segment by Application
5.1 Global Immune Checkpoint Agents Sales by Application (2020-2031)
5.1.1 Global Immune Checkpoint Agents Sales by Application (2020-2025)
5.1.2 Global Immune Checkpoint Agents Sales by Application (2026-2031)
5.1.3 Global Immune Checkpoint Agents Sales Market Share by Application (2020-2031)
5.2 Global Immune Checkpoint Agents Revenue by Application (2020-2031)
5.2.1 Global Immune Checkpoint Agents Revenue by Application (2020-2025)
5.2.2 Global Immune Checkpoint Agents Revenue by Application (2026-2031)
5.2.3 Global Immune Checkpoint Agents Revenue Market Share by Application (2020-2031)
5.3 Global Immune Checkpoint Agents Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Company Information
6.1.2 Bristol Myers Squibb Description and Business Overview
6.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bristol Myers Squibb Immune Checkpoint Agents Product Portfolio
6.1.5 Bristol Myers Squibb Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Immune Checkpoint Agents Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Immune Checkpoint Agents Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca Immune Checkpoint Agents Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Roche
6.4.1 Roche Company Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Immune Checkpoint Agents Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Roche Immune Checkpoint Agents Product Portfolio
6.4.5 Roche Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Immune Checkpoint Agents Industry Chain Analysis
7.2 Immune Checkpoint Agents Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Immune Checkpoint Agents Production Mode & Process Analysis
7.4 Immune Checkpoint Agents Sales and Marketing
7.4.1 Immune Checkpoint Agents Sales Channels
7.4.2 Immune Checkpoint Agents Distributors
7.5 Immune Checkpoint Agents Customer Analysis
8 Immune Checkpoint Agents Market Dynamics
8.1 Immune Checkpoint Agents Industry Trends
8.2 Immune Checkpoint Agents Market Drivers
8.3 Immune Checkpoint Agents Market Challenges
8.4 Immune Checkpoint Agents Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bristol–Myers Squibb
Merck
Astrazeneca plc
Roche
List of Tables
 Table 1. Global Immune Checkpoint Agents Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Immune Checkpoint Agents Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Immune Checkpoint Agents Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Immune Checkpoint Agents Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Immune Checkpoint Agents Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Immune Checkpoint Agents Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Immune Checkpoint Agents Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Immune Checkpoint Agents Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Immune Checkpoint Agents, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Immune Checkpoint Agents, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Immune Checkpoint Agents, Product Type & Application
 Table 12. Global Key Manufacturers of Immune Checkpoint Agents, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Immune Checkpoint Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Checkpoint Agents as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Immune Checkpoint Agents Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Immune Checkpoint Agents Sales by Region (2020-2025) & (K Units)
 Table 18. Global Immune Checkpoint Agents Sales Market Share by Region (2020-2025)
 Table 19. Global Immune Checkpoint Agents Sales by Region (2026-2031) & (K Units)
 Table 20. Global Immune Checkpoint Agents Sales Market Share by Region (2026-2031)
 Table 21. Global Immune Checkpoint Agents Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Immune Checkpoint Agents Revenue Market Share by Region (2020-2025)
 Table 23. Global Immune Checkpoint Agents Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Immune Checkpoint Agents Revenue Market Share by Region (2026-2031)
 Table 25. North America Immune Checkpoint Agents Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
 Table 27. North America Immune Checkpoint Agents Sales by Country (2026-2031) & (K Units)
 Table 28. North America Immune Checkpoint Agents Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Immune Checkpoint Agents Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Immune Checkpoint Agents Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Immune Checkpoint Agents Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Immune Checkpoint Agents Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Immune Checkpoint Agents Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Immune Checkpoint Agents Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Immune Checkpoint Agents Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Immune Checkpoint Agents Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Immune Checkpoint Agents Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Immune Checkpoint Agents Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Immune Checkpoint Agents Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Immune Checkpoint Agents Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Immune Checkpoint Agents Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Immune Checkpoint Agents Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Immune Checkpoint Agents Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Immune Checkpoint Agents Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Immune Checkpoint Agents Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Immune Checkpoint Agents Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Immune Checkpoint Agents Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Immune Checkpoint Agents Sales (K Units) by Type (2020-2025)
 Table 51. Global Immune Checkpoint Agents Sales (K Units) by Type (2026-2031)
 Table 52. Global Immune Checkpoint Agents Sales Market Share by Type (2020-2025)
 Table 53. Global Immune Checkpoint Agents Sales Market Share by Type (2026-2031)
 Table 54. Global Immune Checkpoint Agents Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Immune Checkpoint Agents Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Immune Checkpoint Agents Revenue Market Share by Type (2020-2025)
 Table 57. Global Immune Checkpoint Agents Revenue Market Share by Type (2026-2031)
 Table 58. Global Immune Checkpoint Agents Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Immune Checkpoint Agents Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Immune Checkpoint Agents Sales (K Units) by Application (2020-2025)
 Table 61. Global Immune Checkpoint Agents Sales (K Units) by Application (2026-2031)
 Table 62. Global Immune Checkpoint Agents Sales Market Share by Application (2020-2025)
 Table 63. Global Immune Checkpoint Agents Sales Market Share by Application (2026-2031)
 Table 64. Global Immune Checkpoint Agents Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Immune Checkpoint Agents Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Immune Checkpoint Agents Revenue Market Share by Application (2020-2025)
 Table 67. Global Immune Checkpoint Agents Revenue Market Share by Application (2026-2031)
 Table 68. Global Immune Checkpoint Agents Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Immune Checkpoint Agents Price (USD/Unit) by Application (2026-2031)
 Table 70. Bristol Myers Squibb Company Information
 Table 71. Bristol Myers Squibb Description and Business Overview
 Table 72. Bristol Myers Squibb Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Bristol Myers Squibb Immune Checkpoint Agents Product
 Table 74. Bristol Myers Squibb Recent Developments/Updates
 Table 75. Merck Company Information
 Table 76. Merck Description and Business Overview
 Table 77. Merck Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Merck Immune Checkpoint Agents Product
 Table 79. Merck Recent Developments/Updates
 Table 80. AstraZeneca Company Information
 Table 81. AstraZeneca Description and Business Overview
 Table 82. AstraZeneca Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. AstraZeneca Immune Checkpoint Agents Product
 Table 84. AstraZeneca Recent Developments/Updates
 Table 85. Roche Company Information
 Table 86. Roche Description and Business Overview
 Table 87. Roche Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Roche Immune Checkpoint Agents Product
 Table 89. Roche Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Immune Checkpoint Agents Distributors List
 Table 93. Immune Checkpoint Agents Customers List
 Table 94. Immune Checkpoint Agents Market Trends
 Table 95. Immune Checkpoint Agents Market Drivers
 Table 96. Immune Checkpoint Agents Market Challenges
 Table 97. Immune Checkpoint Agents Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Immune Checkpoint Agents
 Figure 2. Global Immune Checkpoint Agents Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Immune Checkpoint Agents Market Share by Type: 2024 & 2031
 Figure 4. Anti-PD-L1 Drug Product Picture
 Figure 5. Anti-PD-1 Drug Product Picture
 Figure 6. CTLA4 Product Picture
 Figure 7. Global Immune Checkpoint Agents Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Immune Checkpoint Agents Market Share by Application: 2024 & 2031
 Figure 9. Lung Cancer
 Figure 10. Colorectal Cancer
 Figure 11. BreastCancer
 Figure 12. Prostate Cancer
 Figure 13. Melanoma
 Figure 14. Blood Cancers
 Figure 15. Global Immune Checkpoint Agents Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Immune Checkpoint Agents Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Immune Checkpoint Agents Sales (2020-2031) & (K Units)
 Figure 18. Global Immune Checkpoint Agents Average Price (USD/Unit) & (2020-2031)
 Figure 19. Immune Checkpoint Agents Report Years Considered
 Figure 20. Immune Checkpoint Agents Sales Share by Manufacturers in 2024
 Figure 21. Global Immune Checkpoint Agents Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Immune Checkpoint Agents Players: Market Share by Revenue in Immune Checkpoint Agents in 2024
 Figure 23. Immune Checkpoint Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Immune Checkpoint Agents Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Immune Checkpoint Agents Sales Market Share by Country (2020-2031)
 Figure 26. North America Immune Checkpoint Agents Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Immune Checkpoint Agents Sales Market Share by Country (2020-2031)
 Figure 30. Europe Immune Checkpoint Agents Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Immune Checkpoint Agents Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Immune Checkpoint Agents Revenue Market Share by Region (2020-2031)
 Figure 38. China Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Immune Checkpoint Agents Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Immune Checkpoint Agents Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Immune Checkpoint Agents Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Immune Checkpoint Agents Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. U.A.E Immune Checkpoint Agents Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Immune Checkpoint Agents by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Immune Checkpoint Agents by Type (2020-2031)
 Figure 60. Global Immune Checkpoint Agents Price (USD/Unit) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Immune Checkpoint Agents by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Immune Checkpoint Agents by Application (2020-2031)
 Figure 63. Global Immune Checkpoint Agents Price (USD/Unit) by Application (2020-2031)
 Figure 64. Immune Checkpoint Agents Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Immune Checkpoint Blockers Market Research Report 2025
Global Immunological Agents Market Research Report 2024
Global Immune Adjuvant Market Research Report 2024
Global PD 1 and PD L1 Monoclonal Antibody Market Research Report 2025
Global Tumor Immunity Therapy Market Research Report 2024
Global Health Product for Immune Market Research Report 2024
Global Pembrolizumab Market Research Report 2024
Global Allergy Immunotherapies Market Research Report 2025
PD 1 and PD L1 Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immuno Oncology Treatment Market Insights Forecast to 2030
Global PD 1 Inhibitor Market Research Report 2024
Global Immunity Boosting Food Market Research Report 2024
Global Nivolumab Market Research Report 2024
Global Avelumab Market Research Report 2024
Global Neutralizing Agent Market Research Report 2025
lmmune Checkpoint Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immune System Booster Market Research Report 2024
Global Cell Based Immunotherapy Market Research Report 2024
Global PD 1 and PD L1 Antibody Market Insights Forecast to 2030
Global Checkpoint Inhibitor Refractory Cancer Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions